Clinical trials: Temozolomide
Glioma, Glioblastoma Multiforme
Temozolomide Chronotherapy for High Grade Glioma
Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone.
- Trial name
- NCT02781792
- Testing
- Temozolomide, Functional Assessment of Cancer Therapy - Brain, ActTrust Condor Instrument Watch
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Newly Diagnosed Glioblastoma
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
This is a phase 1/2, randomized, placebo-controlled study to evaluate safety, tolerability, anti-tumor activity and impact on absolute lymphocyte count of GX-I7 plus adjuvant temozolomide combination regimen in patients with…
- Trial name
- NCT04065087
- Testing
- GX-I7
- Where
- South Korea
- Sponsor
- Genexine, Inc.
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Colorectal Adenocarcinoma
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient).
- Trial name
- NCT04457284
- Testing
- Temozolomide (TMZ), Cisplatin, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care.
- Trial name
- NCT02177578
- Testing
- Temozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)
Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.
Glioblastoma (GBM) is an aggressive cancer with a progression-free survival (PFS) of 7 months and an overall survival (OS) of 15 months. Many therapeutic approaches have failed to improve the prognosis of patients to date.
- Conditions
- Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide
- Trial name
- SonoFIRST (NCT04614493)
- Testing
- SonoCloud-9 (SC9) device, Temozolomide according Stupp protocol
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High Grade Glioma
Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
The investigators of this study want to see if shortening the total treatment time for brain tumors is safe.The treatment for participant's brain tumors is laser surgery (Laser Interstitial Thermal Therapy (LITT)) followed by…
- Trial name
- NCT02970448
- Testing
- LITT, Radiation therapy, Temozolomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
The purpose of this study is to evaluate the safety of vismodegib in combination with temozolomide (primary objective - phase I) and to estimate the efficacy of vismodegib in combination with temozolomide in adult patients with…
- Trial name
- NCT01601184
- Testing
- vismodegib, Temozolomide
- Where
- 15 sites in France, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- Centre Leon Berard
Glioblastoma Multiforme
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM).
- Trial name
- NCT04421378
- Testing
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
- Where
- 18 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Karyopharm Therapeutics Inc
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption. Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide…
- Trial name
- ExCentric (NCT01124240)
- Testing
- Cilengitide
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Northern Sydney and Central Coast Area Health Service
Neuroblastoma, Medulloblastoma
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug).
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Trial name
- NCT00867568
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Giselle Sholler
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Lung Small Cell Carcinoma
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This randomized phase II trial studies how well temozolomide with or without veliparib works in treating patients with small cell lung cancer that has returned or does not respond to treatment.
- Trial name
- NCT01638546
- Testing
- Laboratory Biomarker Analysis, Temozolomide, Veliparib
- Where
- 14 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed and Recurrent Glioblastoma
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
This study will investigate different doses of [177Lu]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of…
- Trial name
- NCT05739942
- Testing
- [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Pituitary Adenomas
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
The purpose of this study was to determine whether radiotherapy combined with Temozolomide is more effective than radiotherapy alone in the treatment of patients with refractory pituitary adenomas.
- Trial name
- NCT04244708
- Testing
- Radiotherapy plus temozolomide
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Gliomas
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
- Trial name
- NCT01670890
- Testing
- TMZ, TMZ plus CDDP
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Glioblastomas, Gliosarcoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress.
- Trial name
- HBO (NCT00936052)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Neurological Surgery, P.C.
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT…
- Trial name
- NCT04396860
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab
- Where
- 285 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)